## USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

**Procurement and Supply Management** 

## THE DOLUTEGRAVIR FORECASTING TOOL:

Supporting supply chain planning for a smooth transition to TLD

The inclusion in WHO HIV treatment guidelines and recent market introduction of the ARV fixed-dose formulation tenofovir/lamivudine/dolutegravir (TLD) has driven many national HIV/AIDS programs to consider the transition of patients to this new regimen. Yet the implementation of a new drug regimen requires careful supply chain planning.

GHSC-PSM has developed a forecasting tool to help programs understand TLD product requirements and recommended procurements, based on their transition plan. Within the tool, programs can develop transition plans that consider aspects such as transition timeframe, duration, and targeted patient groups. The tool can also project the impact of new product introduction on legacy regimen consumption and recommended procurements, supporting programs in the development of transition plans that maximize the use of available resources and minimize waste of legacy product.

The tool will enable programs to implement their TLD policy by

The Dolutegravir Forecasting Tool will enable programs to implement their TLD policy by providing a preliminary forecast and procurement plan.

To request the tool: Email: TLDinfo@ghsc-psm.org

For more information: www.GHSupplyChain.org/TLD

providing a preliminary forecast and procurement plan. GHSC-PSM encourages programs to utilize insights from the tool in conjunction with their normal quantification process and tools in planning their TLD introduction.

Outputs from the tool include:

- Projected TLD consumption, stock-on-hand, and months-of-stock, based on forecasted consumption and orders at the start of transition for up to three years
- Projected key legacy formulation consumption, stock-on-hand, and months-of-stock, based on forecasted consumption and orders at the start of transition for up to three years
- Recommended planned orders by quantity and date for TLD and/or legacy formulations
- Quantity of patients on TLD vs legacy formulations month-by-month
- Quantity of TLD patients by initiation type (new ART initiation, transition from legacy formulation)
- Graphical representations of the above



